<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>pharmaphorum &#187; R&amp;D</title>
	<atom:link href="http://www.pharmaphorum.com/category/rd/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaphorum.com</link>
	<description>Bringing Healthcare Together</description>
	<lastBuildDate>Fri, 03 Feb 2012 10:52:03 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>The EU generics market: a Greek perspective</title>
		<link>http://www.pharmaphorum.com/2012/01/10/the-eu-generics-market-a-greek-perspective/</link>
		<comments>http://www.pharmaphorum.com/2012/01/10/the-eu-generics-market-a-greek-perspective/#comments</comments>
		<pubDate>Tue, 10 Jan 2012 11:00:34 +0000</pubDate>
		<dc:creator>RachelASharpe</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[General]]></category>
		<category><![CDATA[Interviews]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=6599</guid>
		<description><![CDATA[Rebecca Aris speaks with the head of the R&#038;D department for generic product development at Genepharm for his insights into the current trends in the EU generics market.

Ahead of his speaking engagement at the Generics &#038; Biosimilars summit 2012, Deepak shares his insights...]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2012/01/10/the-eu-generics-market-a-greek-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma emerging markets: what is Latin America’s place within R&amp;D?</title>
		<link>http://www.pharmaphorum.com/2011/05/11/pharma-emerging-markets-what-is-latin-america%e2%80%99s-place-within-rd/</link>
		<comments>http://www.pharmaphorum.com/2011/05/11/pharma-emerging-markets-what-is-latin-america%e2%80%99s-place-within-rd/#comments</comments>
		<pubDate>Wed, 11 May 2011 13:00:59 +0000</pubDate>
		<dc:creator>Rebecca</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[General]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=4195</guid>
		<description><![CDATA[As Latin American markets grow the region offers more attractive opportunities in the research and development field.  Here Ruben Gennero and Valentina Jaramillo discuss the pros and cons of R&#038;D in this area.

In a previous post we examined the opportunities offered by Latin-American markets in the pharmaceutical field. The huge…
]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2011/05/11/pharma-emerging-markets-what-is-latin-america%e2%80%99s-place-within-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trends in pharmaceutical R&amp;D outsourcing</title>
		<link>http://www.pharmaphorum.com/2010/09/03/trends-in-pharmaceutical-rd-outsourcing/</link>
		<comments>http://www.pharmaphorum.com/2010/09/03/trends-in-pharmaceutical-rd-outsourcing/#comments</comments>
		<pubDate>Fri, 03 Sep 2010 08:59:03 +0000</pubDate>
		<dc:creator>Rebecca</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[General]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=2640</guid>
		<description><![CDATA[As pressure to cut costs in the pharma industry continues, Adwait Bhagwat discusses the increasing trend to outsource R&#038;D.

R&#038;D outsourcing involves pharmaceutical companies subcontracting parts of their R&#038;D efforts to third-party service providers...
]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/09/03/trends-in-pharmaceutical-rd-outsourcing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The role of social media in clinical trial recruitment</title>
		<link>http://www.pharmaphorum.com/2010/07/07/the-role-of-social-media-in-clinical-trial-recruitment/</link>
		<comments>http://www.pharmaphorum.com/2010/07/07/the-role-of-social-media-in-clinical-trial-recruitment/#comments</comments>
		<pubDate>Wed, 07 Jul 2010 10:28:18 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[facebook]]></category>
		<category><![CDATA[myspace]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[social media]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=2283</guid>
		<description><![CDATA[As social media permeates all aspects of healthcare, Sean Johnson explores what role it can play in supporting clinical trial recruitment.

The biggest barrier for pharmaceutical companies to overcome in conducting a clinical trial is actually recruiting patients to participate. This recruiting conundrum has… ]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/07/07/the-role-of-social-media-in-clinical-trial-recruitment/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
		</item>
		<item>
		<title>The growth of drug development in emerging markets</title>
		<link>http://www.pharmaphorum.com/2010/06/28/the-growth-of-drug-development-in-emerging-markets/</link>
		<comments>http://www.pharmaphorum.com/2010/06/28/the-growth-of-drug-development-in-emerging-markets/#comments</comments>
		<pubDate>Mon, 28 Jun 2010 14:01:43 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Interviews]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=2214</guid>
		<description><![CDATA[Continuing our interview series, Nathaniel Ramuthaga discusses with pharmaphorum how the clinical research environment is developing in the emerging markets.

It seems that an ever increasing volume of clinical study work is being conducted outside the mature global pharma markets... ]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/06/28/the-growth-of-drug-development-in-emerging-markets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Are IDEAs Made Of: Phase III</title>
		<link>http://www.pharmaphorum.com/2010/03/19/what-are-ideas-made-of-phase-iii/</link>
		<comments>http://www.pharmaphorum.com/2010/03/19/what-are-ideas-made-of-phase-iii/#comments</comments>
		<pubDate>Fri, 19 Mar 2010 11:05:23 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[strategy]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=1415</guid>
		<description><![CDATA[Well, you asked for more R&#038;D articles, so this week Mike Rea turns his thoughts to phase III trials and what might be going wrong.

Patient: "I've just gone into phase III! What are my chances of coming through alive?" Doctor: "Well the prognosis is not good - about 20%"]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/03/19/what-are-ideas-made-of-phase-iii/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Minimising risks: drug discovery practices for Chief Scientific Officers</title>
		<link>http://www.pharmaphorum.com/2010/02/02/minimising-risks-drug-discovery-practices-for-chief-scientific-officers/</link>
		<comments>http://www.pharmaphorum.com/2010/02/02/minimising-risks-drug-discovery-practices-for-chief-scientific-officers/#comments</comments>
		<pubDate>Tue, 02 Feb 2010 14:52:47 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[strategy]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=1205</guid>
		<description><![CDATA[pharmaphorum invites feedback from our readers on the recent interview marcus evans conducted with Malcolm Weir, CEO of Heptares Therapeutics, discussing the challenges of drug discovery today.

Statistics seem almost stacked against developing a fitting drug for a target disease. Drug discovery is plagued by time consuming and costly...]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/02/02/minimising-risks-drug-discovery-practices-for-chief-scientific-officers/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Difficult issues in pharma going global (part II)</title>
		<link>http://www.pharmaphorum.com/2010/01/14/difficult-issues-in-pharma-going-global-part-ii/</link>
		<comments>http://www.pharmaphorum.com/2010/01/14/difficult-issues-in-pharma-going-global-part-ii/#comments</comments>
		<pubDate>Thu, 14 Jan 2010 09:23:57 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=1113</guid>
		<description><![CDATA[In the concluding part of this two part article, Faiz Kermani explores regulations to control trials in emerging markets and asks whether pharma is being ethical enough in these regions.

In the first part of this article I looked at the growth of clinical development activity in the emerging pharma markets...]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/01/14/difficult-issues-in-pharma-going-global-part-ii/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Difficult issues in pharma going global (part I)</title>
		<link>http://www.pharmaphorum.com/2010/01/12/difficult-issues-in-pharma-going-global-part-i/</link>
		<comments>http://www.pharmaphorum.com/2010/01/12/difficult-issues-in-pharma-going-global-part-i/#comments</comments>
		<pubDate>Tue, 12 Jan 2010 08:27:02 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=1097</guid>
		<description><![CDATA[In the first piece of a two part article, Faiz Kermani looks at the emergence of clinical trial activity in emerging markets and explores some of the ethical issues.

Although the economic downturn has had a negative impact, the global pharmaceutical market is still experiencing strong growth...
]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2010/01/12/difficult-issues-in-pharma-going-global-part-i/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>A ghostly undertaking</title>
		<link>http://www.pharmaphorum.com/2009/11/24/a-ghostly-undertaking/</link>
		<comments>http://www.pharmaphorum.com/2009/11/24/a-ghostly-undertaking/#comments</comments>
		<pubDate>Tue, 24 Nov 2009 08:47:44 +0000</pubDate>
		<dc:creator>Paul</dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://www.pharmaphorum.com/?p=787</guid>
		<description><![CDATA[As medical ghostwriting comes under increasing scrutiny, Les Rose asks whether the ability to communicate in writing should not be a specialism in its own right.

Many years ago I was the project manager of a large clinical study. I ran the study, did most of the data management and a good deal of the analysis, and then left the company for pastures new. Someone else came on board and wrote up the results...]]></description>
		<wfw:commentRss>http://www.pharmaphorum.com/2009/11/24/a-ghostly-undertaking/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
	</channel>
</rss>

